Medication persistence with ginkgo biloba drugs of different dosage strengths - Persistenz bei Ginkgo biloba-Arzneimitteln unterschiedlicher Wirkstärke.

Czeche S Schüssel K Burkart M Franzmann A Schulz M

19. Jahrestagung der GAA Gesellschaft für Arzneimittelforschung und Arzneimittelepidemiologie - 19th Annual Meeting of the German Drug Utilisation Research Group (GAA), 22.11. - 23.11.2012, Jena.

www.egms.de/static/en/meetings/gaa2012/12gaa13.shtml

Conflicts of interests: Diese Studie wurde finanziell unterstützt durch Dr. Willmar Schwabe GmbH & Co. KG. MB ist Angestellter bei Dr. Willmar Schwabe GmbH & Co. KG. This study was financially supported by Dr. Willmar Schwabe GmbH & Co. KG. MB is employee of Dr. Willmar Schwabe GmbH & Co. KG.

Pharmakoepidemiologische Auswertungen des DAPI

Impact On Antihypertensive Prescribing After The Dear Healthcare Professional Letter On Increased Risk Of Skin Cancer Related To Hydrochlorothiazide

Infliximab And Etanercept Biosimilars And Originators: Learnings From Regional Market Dynamics In Germany

Utilization of drugs with reports on potential efficacy or harm on COVID-19 before, during, and after the first pandemic wave

Verordnungsqualität oraler Fluorchinolone in den deutschen Bundesländern 2014 bis 2019

Use of fixed‑dose combination antihypertensives in Germany between 2016 and 2020: an example of guideline inertia

Masterthesis - Utilization of drugs with reports on potential efficacy or harm on COVID-19 before, during, and after the first pandemic wave